/VCYT
VCYT Stock - Veracyte, Inc.
Healthcare|BiotechnologyNASDAQ
$42.92+2.09%
+$0.88 (+2.09%) • Dec 19
63
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.91
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).59
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.47
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+4.3%upside
Target: $44.77
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for VCYT
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$42.49 – $43.35
TARGET (TP)$44.75
STOP LOSS$39.49
RISK/REWARD1:0.5
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta1.83
52W High$50.71
52W Low$22.61
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $445.76M | $361.05M | $296.54M | $219.51M | $117.48M |
| Gross Profit | $298.14M | $248.15M | $194.95M | $145.11M | $76.03M |
| Gross Margin | 66.9% | 68.7% | 65.7% | 66.1% | 64.7% |
| Operating Income | $16.14M | $-85,795,000 | $-41,081,000 | $-81,903,000 | $-35,389,000 |
| Net Income | $24.14M | $-74,404,000 | $-36,560,000 | $-75,563,000 | $-34,909,000 |
| Net Margin | 5.4% | -20.6% | -12.3% | -34.4% | -29.7% |
| EPS | $0.32 | $-1.02 | $-0.51 | $-1.11 | $-0.66 |
Company Overview
Veracyte, Inc. operates as a diagnostics company worldwide. The company offers Afirma Genomic Sequencing Classifier and Xpression Atlas, which are used to determine patients with indeterminate results are benign to avoid unnecessary surgery; Decipher Prostate Biopsy and Radical Prostatectomy for prostate cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; Percepta Genomic Sequencing Classifier and Percepta Nasal Swab Test for lung cancer diagnosis; Envisia Genomic Classifier for diagnosing interstitial lung disease, including idiopathic pulmonary fibrosis; and Immunoscore Colon Cancer test for colon cancer diagnosis. It is also developing Percepta Genomic Atlas to help inform lung cancer treatment decisions; Envisia Classifier, the nCounter analysis system; and LymphMark for lymphoma subtyping test. Veracyte, Inc. has technology licensing and collaboration arrangements with Johnson & Johnson; Acerta Pharma; and CareDx. The company was formerly known as Calderome, Inc. and changed its name to Veracyte, Inc. in March 2008. Veracyte, Inc. was incorporated in 2006 and is headquartered in South San Francisco, California.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
6
75%
Hold / Neutral
2
25%
Sell / Underperform
0%
Analyst Consensus🟢 Bullish
6 Bullish2 Neutral/Bearish
Price Targets
$41
Average Target
↓ 4.5% Downside
Now
$33
Low
$41
Average
$50
High
Based on 9 analysts
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| December 2nd 2025 | Morgan Stanley | Resumed | Underweight | $48 |
| October 20th 2025 | Canaccord Genuity | Initiation | Hold | $40 |
| March 20th 2025 | Craig Hallum | Initiation | Buy | $45 |
| December 5th 2024 | Goldman | Downgrade | Neutral | $37← $38 |
| November 15th 2024 | Wolfe Research | Initiation | Outperform | $50 |
| October 16th 2024 | UBS | Initiation | Buy | $43 |
| October 10th 2024 | Guggenheim | Initiation | Buy | $40 |
| February 23rd 2024 | Needham | Reiterated | Buy | $33← $30 |
| January 18th 2023 | Raymond James | Downgrade | Market Perform | - |
| January 5th 2023 | Scotiabank | Initiation | Sector Outperform | $33 |
Earnings History & Surprises
VCYTBeat Rate
94%
Last 18 quarters
Avg Surprise
+112.6%
EPS vs Estimate
Beats / Misses
17/1
Last 12 quarters
Latest EPS
$0.51
Q4 2025
EPS Surprise History
Q1 24
+42.9%
$-0.04vs$-0.07
Q2 24
+89.5%
$-0.02vs$-0.19
Q3 24
+530.8%
$0.30vs$0.05
Q4 24
+603.7%
$0.19vs$0.03
Q1 25
+260.0%
$0.36vs$0.10
Q2 25
+55.0%
$0.31vs$0.20
Q3 25
+41.9%
$0.44vs$0.31
Q4 25
+59.4%
$0.51vs$0.32
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 5, 2026 | — | — | — | — |
Q1 2026 | Feb 23, 2026 | $0.40 | — | — | — |
Q4 2025 | Nov 4, 2025 | $0.32 | $0.51 | +59.4% | ✓ BEAT |
Q3 2025 | Aug 6, 2025 | $0.31 | $0.44 | +41.9% | ✓ BEAT |
Q2 2025 | May 7, 2025 | $0.20 | $0.31 | +55.0% | ✓ BEAT |
Q1 2025 | Feb 24, 2025 | $0.10 | $0.36 | +260.0% | ✓ BEAT |
Q4 2024 | Nov 6, 2024 | $0.03 | $0.19 | +603.7% | ✓ BEAT |
Q3 2024 | Aug 6, 2024 | $0.05 | $0.30 | +530.8% | ✓ BEAT |
Q2 2024 | May 7, 2024 | $-0.19 | $-0.02 | +89.5% | ✓ BEAT |
Q1 2024 | Feb 22, 2024 | $-0.07 | $-0.04 | +42.9% | ✓ BEAT |
Q4 2023 | Nov 7, 2023 | $-0.16 | $-0.03 | +81.3% | ✓ BEAT |
Q3 2023 | Aug 8, 2023 | $-0.16 | $-0.12 | +25.0% | ✓ BEAT |
Q2 2023 | May 4, 2023 | $-0.14 | $-0.11 | +21.4% | ✓ BEAT |
Q1 2023 | Feb 22, 2023 | $-0.15 | $-0.05 | +66.7% | ✓ BEAT |
Q4 2022 | Nov 2, 2022 | $-0.24 | $-0.12 | +50.0% | ✓ BEAT |
Q3 2022 | Aug 2, 2022 | $-0.21 | $-0.13 | +38.1% | ✓ BEAT |
Q2 2022 | May 3, 2022 | $-0.23 | $-0.20 | +13.0% | ✓ BEAT |
Q1 2022 | Feb 28, 2022 | $-0.14 | $-0.15 | -7.1% | ✗ MISS |
Q4 2021 | Nov 9, 2021 | $-0.14 | $-0.13 | +7.1% | ✓ BEAT |
Q3 2021 | Jul 29, 2021 | $-0.25 | $-0.13 | +48.0% | ✓ BEAT |
Latest News
Morgan Stanley Maintains Underweight on Veracyte, Raises Price Target to $48
➖ NeutralBenzinga•Dec 2, 2025, 06:02 PM
Morgan Stanley Maintains Underweight on Veracyte, Raises Price Target to $40
➖ NeutralBenzinga•Nov 11, 2025, 04:58 PM
UBS Maintains Buy on Veracyte, Raises Price Target to $48
📈 PositiveBenzinga•Nov 5, 2025, 11:08 PM
Veracyte shares are trading higher. Multiple firms raised their price targets on the stock.
📈 PositiveBenzinga•Nov 5, 2025, 08:25 PM
Canaccord Genuity Maintains Hold on Veracyte, Raises Price Target to $43
➖ NeutralBenzinga•Nov 5, 2025, 06:36 PM•Also:
Guggenheim Maintains Buy on Veracyte, Raises Price Target to $45
📈 PositiveBenzinga•Nov 5, 2025, 03:06 PM
Needham Maintains Buy on Veracyte, Raises Price Target to $44
📈 PositiveBenzinga•Nov 5, 2025, 11:02 AM
Veracyte shares are trading higher after the company reported better-than-expected Q3 financial results and raised its FY25 sales guidance above estimates
📈 PositiveBenzinga•Nov 4, 2025, 10:08 PM
Veracyte Raises FY2025 Sales Guidance from $496.000M-$504.000M to $506.000M-$510.000M vs $500.497M Est
📈 PositiveBenzinga•Nov 4, 2025, 09:09 PM
Veracyte Q3 Adj. EPS $0.51 Beats $0.13 Estimate, Sales $131.900M Beat $124.917M Estimate
📈 PositiveBenzinga•Nov 4, 2025, 09:08 PM
Veracyte Publishes Studies Demonstrating Afirma Genomic Resource For Intelligent Discovery Tool For Future Of Thyroid Nodule Evaluation
📈 PositiveBenzinga•Nov 3, 2025, 09:28 PM
Canaccord Genuity Initiates Coverage On Veracyte with Hold Rating, Announces Price Target of $40
➖ NeutralBenzinga•Oct 20, 2025, 10:46 AM•Also:
Freedom Capital Markets Initiates Coverage On Veracyte with Buy Rating, Announces Price Target of $45
📈 PositiveBenzinga•Oct 17, 2025, 12:23 PM
Reported Sunday, Veracyte Announces BALANCE Trial Results Showing PAM50 Biomarker Predicts Apalutamide Benefit With Salvage Radiation In Prostate Cancer
📈 PositiveBenzinga•Sep 29, 2025, 06:34 AM
Veracyte To Present First Prospective Data Predicting Hormone Therapy Benefit In Recurrent Prostate Cancer At ASTRO 2025
📈 PositiveBenzinga•Sep 24, 2025, 01:08 PM
Veracyte Completes Enrollment Of 2,400 Patients In NIGHTINGALE Trial For Percepta Nasal Swab Lung Cancer Test
📈 PositiveBenzinga•Aug 26, 2025, 12:36 PM
Veracyte to replace Triumph in S&P SmallCap 600 index
📈 PositiveSeeking Alpha•Jul 25, 2025, 11:42 AM
Frequently Asked Questions about VCYT
What is VCYT's current stock price?
Veracyte, Inc. (VCYT) is currently trading at $42.92 per share. The stock has moved +2.09% today.
What is the analyst price target for VCYT?
The average analyst price target for VCYT is $44.75, based on 1 analyst.
What sector is Veracyte, Inc. in?
Veracyte, Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is VCYT's market cap?
Veracyte, Inc. has a market capitalization of $3.39 billion, making it a mid-cap company.
Does VCYT pay dividends?
No, Veracyte, Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorADPT
Adaptive Biotechnologies Corporation
$17.00
Mkt Cap: $2.6B
APLS
Apellis Pharmaceuticals, Inc.
$24.65
Mkt Cap: $3.1B
FOLD
Amicus Therapeutics, Inc.
$14.18
Mkt Cap: $4.4B
IDYA
IDEAYA Biosciences, Inc.
$33.55
Mkt Cap: $2.9B
IRON
Disc Medicine, Inc.
$80.04
Mkt Cap: $3.0B
KNSA
Kiniksa Pharmaceuticals, Ltd.
$43.19
Mkt Cap: $3.2B
LEGN
Legend Biotech Corporation
$21.92
Mkt Cap: $2.0B
SRRK
Scholar Rock Holding Corporation
$43.90
Mkt Cap: $4.5B
TARS
Tarsus Pharmaceuticals, Inc.
$81.40
Mkt Cap: $3.5B
ZLAB
Zai Lab Limited
$18.04
Mkt Cap: $2.0B
Explore stocks similar to VCYT for comparison